- Home
- STRO vs CNTX Comparison
STRO vs CNTX Comparison
Compare STRO & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CNTX
- Stock Information
- Founded
- STRO 2003
- CNTX 2015
- Country
- STRO United States
- CNTX United States
- Employees
- STRO N/A
- CNTX N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- CNTX Health Care
- Exchange
- STRO Nasdaq
- CNTX Nasdaq
- Market Cap
- STRO 76.5M
- CNTX 75.6M
- IPO Year
- STRO 2018
- CNTX 2021
- Fundamental
- Price
- STRO $0.91
- CNTX $1.10
- Analyst Decision
- STRO Hold
- CNTX Strong Buy
- Analyst Count
- STRO 7
- CNTX 7
- Target Price
- STRO $1.97
- CNTX $5.20
- AVG Volume (30 Days)
- STRO 480.6K
- CNTX 204.2K
- Earning Date
- STRO 11-12-2025
- CNTX 11-05-2025
- Dividend Yield
- STRO N/A
- CNTX N/A
- EPS Growth
- STRO N/A
- CNTX N/A
- EPS
- STRO N/A
- CNTX N/A
- Revenue
- STRO $104,473,000.00
- CNTX N/A
- Revenue This Year
- STRO $65.48
- CNTX N/A
- Revenue Next Year
- STRO N/A
- CNTX N/A
- P/E Ratio
- STRO N/A
- CNTX N/A
- Revenue Growth
- STRO N/A
- CNTX N/A
- 52 Week Low
- STRO $0.52
- CNTX $0.49
- 52 Week High
- STRO $4.60
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- STRO 52.61
- CNTX 73.54
- Support Level
- STRO $0.84
- CNTX $0.85
- Resistance Level
- STRO $0.95
- CNTX $0.99
- Average True Range (ATR)
- STRO 0.06
- CNTX 0.07
- MACD
- STRO -0.00
- CNTX 0.01
- Stochastic Oscillator
- STRO 65.42
- CNTX 82.25
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.